Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.

Nikiphorou E, Hall FC.

Rheumatology (Oxford). 2014 Oct;53(10):1906-7. doi: 10.1093/rheumatology/keu161. Epub 2014 Apr 11. No abstract available.

PMID:
24729401
2.

Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.

Lehner GF, Brunner-Palka M, Rettenbacher T, Schmidauer R, Herold M.

Rheumatology (Oxford). 2014 Jul;53(7):1349-50. doi: 10.1093/rheumatology/ket458. Epub 2014 Jan 20. No abstract available.

PMID:
24446469
3.

Treatment approaches in primary Sjogren syndrome.

Vissink A, Kallenberg CG, Bootsma H.

JAMA. 2010 Nov 10;304(18):2015-6; author reply 2016. doi: 10.1001/jama.2010.1582. No abstract available.

PMID:
21063008
4.

Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab.

Uraoka Y, Tanigawa T, Watanabe K, Machida H, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Watanabe T, Fujiwara Y, Arakawa T.

Am J Gastroenterol. 2012 Aug;107(8):1266-8. doi: 10.1038/ajg.2012.92. No abstract available.

PMID:
22859008
5.

Rituximab and lupus interstitial lung disease: friend or foe?

Efthimiou P, Kukar M, Hersh A.

Int J Rheum Dis. 2011 Feb;14(1):e3-4. doi: 10.1111/j.1756-185X.2010.01592.x. Epub 2011 Jan 24. No abstract available.

PMID:
21303472
6.

EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.

Moerman RV, Arends S, Meiners PM, Brouwer E, Spijkervet FK, Kroese FG, Vissink A, Bootsma H.

Ann Rheum Dis. 2014 Feb;73(2):472-4. doi: 10.1136/annrheumdis-2013-203736. Epub 2013 Aug 12. No abstract available.

PMID:
23940214
7.

[Efficiency of rituximab in an unusual form of primary Sjögren's syndrome: a case report].

Mrabet D, Meddeb N, Sahli H, Saadi F, Chéour E, Elleuch M, Sellami S.

Therapie. 2010 Nov-Dec;65(6):581-3. French. No abstract available.

PMID:
23189757
8.

Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.

Ciccia F, Giardina A, Rizzo A, Guggino G, Cipriani P, Carubbi F, Giacomelli R, Triolo G.

Ann Rheum Dis. 2013 May;72(5):782-3. doi: 10.1136/annrheumdis-2012-202754. Epub 2012 Dec 21. No abstract available.

PMID:
23264342
9.

Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.

Mekinian A, Ravaud P, Hatron PY, Larroche C, Leone J, Gombert B, Hamidou M, Cantagrel A, Marcelli C, Rist S, Breban M, Launay D, Fain O, Gottenberg JE, Mariette X.

Ann Rheum Dis. 2012 Jan;71(1):84-7. doi: 10.1136/annrheumdis-2011-200086. Epub 2011 Sep 16.

PMID:
21926185
10.

[Sjögren's syndrome: a new approach to treatment].

Rossier V, Bart PA, Spertini F.

Rev Med Suisse. 2012 Apr 18;8(337):843-7. French.

PMID:
22594008
11.

Treatment of primary Sjögren syndrome with rituximab.

Faustman DL, Vivino FB, Carsons SE.

Ann Intern Med. 2014 Sep 2;161(5):376-7. doi: 10.7326/L14-5017-3. No abstract available.

PMID:
25178574
12.

Treatment of primary Sjögren syndrome with rituximab. In response.

Saraux A, Nowak E, Devauchelle-Pensec V.

Ann Intern Med. 2014 Sep 2;161(5):377-8. doi: 10.7326/L14-5017-4. No abstract available.

PMID:
25178575
13.

Does rituximab help patients with primary Sjögren syndrome?

[No authors listed]

Ann Intern Med. 2014 Feb 18;160(4):I-11. doi: 10.7326/P14-9005. No abstract available.

PMID:
24727838
14.

Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.

Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, Pertuiset E, Kaplanski G, Chiche L, Berthelot JM, Gombert B, Goupille P, Marcelli C, Feuillet S, Leone J, Sibilia J, Zarnitsky C, Carli P, Rist S, Gaudin P, Salliot C, Piperno M, Deplas A, Breban M, Lequerre T, Richette P, Ghiringhelli C, Hamidou M, Ravaud P, Mariette X; Club Rhumatismes et Inflammations and the French Society of Rheumatology.

Ann Rheum Dis. 2013 Jun;72(6):1026-31. doi: 10.1136/annrheumdis-2012-202293. Epub 2012 Dec 21.

PMID:
23264337
15.

Summaries for patients. Does rituximab help patients with primary Sjögren syndrome?

[No authors listed]

Ann Intern Med. 2014 Feb 18;160(4):I-11. No abstract available.

PMID:
25006621
16.

Successful treatment of a patient with primary Sjögren's syndrome with Rituximab.

Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B.

Clin Rheumatol. 2006 Nov;25(6):891-4. Epub 2005 Nov 8.

PMID:
16283417
17.

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.

Pollard RP, Abdulahad WH, Vissink A, Hamza N, Burgerhof JG, Meijer JM, Visser A, Huitema MG, Spijkervet FK, Kallenberg CG, Bootsma H, Kroese FG.

Ann Rheum Dis. 2013 Jan;72(1):146-8. doi: 10.1136/annrheumdis-2012-202071. Epub 2012 Jul 31. No abstract available.

PMID:
22851468
18.

Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry.

Mekinian A, Ravaud P, Larroche C, Hachulla E, Gombert B, Blanchard-Delaunay C, Cantagrel A, Fain O, Sibilia J, Gottenberg JE, Mariette X; Club Rhumatismes et Inflammation.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):208-12. Epub 2012 Apr 13.

PMID:
22341206
19.

Sustained response to rituximab in a patient with Sjögren´s syndrome and severe refractory polyneuropathy.

Pertovaara M, Korpela M.

Clin Exp Rheumatol. 2012 Sep-Oct;30(5):808; author reply 809. Epub 2012 Oct 17. No abstract available.

PMID:
22992382
20.

Acquired factor VIII inhibitor in Sjögren's syndrome.

Vintimilla M, Joseph A, Ranganathan P.

Arthritis Care Res (Hoboken). 2010 Jul;62(7):1047-50. doi: 10.1002/acr.20147. No abstract available.

Supplemental Content

Support Center